A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer

YEN-SHEN LULee K.S.Chao T.-Y.Tseng L.-M.Chitapanarux I.Chen S.-C.Liu C.-T.Sohn J.Kim J.H.Chang Y.-C.Yang Y.Shotelersuk K.Jung K.H.Valenti R.Slader C.Gao M.Park Y.H.2021-03-102021-03-1020211078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100350018&doi=10.1158%2f1078-0432.CCR-20-1008&partnerID=40&md5=3d2229a8780dbb4effd5e4822ce87cebhttps://scholars.lib.ntu.edu.tw/handle/123456789/551329[SDGs]SDG3A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancerjournal article10.1158/1078-0432.CCR-20-1008327189972-s2.0-85100350018